Sanofi to Pay Regeneron Up to $8 Billion in Expanded Drug Development Pact

Sanofi SA will pay its long-term partner Regeneron $1 billion upfront to expand their collaboration on four new long-acting medicines for inflammatory diseases, a deal with a potential total value of up to $8 billion. The agreement aims to build the French drugmaker's pipeline beyond its blockbuster treatment, Dupixent, which the two companies also co-developed.

Deal Structure and Financials

Under the terms announced by the companies on Thursday, Sanofi's initial payment will be followed by up to $7 billion in additional milestone payments. These future payments are contingent on the new drugs achieving specific development, regulatory, and sales targets.

The partnership calls for the two companies to jointly develop and commercialize four new antibody-based medicines. Development and sales costs, as well as potential profits, will be split equally worldwide. Regeneron is set to lead the development of the medicines, while Sanofi will be responsible for global sales.

Strategic Rationale and Pipeline

The collaboration gives Sanofi access to promising new treatments as it seeks to diversify its revenue streams beyond Dupixent. For Regeneron, the deal secures a powerful commercial partner while allowing it to retain a significant role in development and a large share of future profits.

Ad

The agreement covers several assets at different stages:

• REGN20423: The first drug is already in an early-stage clinical study for atopic dermatitis.
• Three other medicines: These are in earlier stages of development, with human testing anticipated to begin in 2027.
• Lunsekimig: Regeneron will have an option to add Sanofi’s experimental drug for chronic obstructive pulmonary disease (COPD) to the partnership after it completes late-stage testing.

Existing Partnership Unchanged

The companies confirmed that their existing, highly successful agreement for Dupixent will remain unchanged. Dupixent treats a range of inflammatory conditions and is a major revenue driver for Sanofi. As part of the new deal, the firms also settled a previous legal dispute, though no further details on the settlement were provided.